Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.98 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.98 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.98 |
| ▸ | PGR | P06401 | 3/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | SHBG | P04278 | 2/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.98 |
| ▸ | MAPT | P10636 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | AR | P10275 | 2/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL8801457 | 1.00 | HIF1A (0.98) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL1010584 | 1.00 | HIF1A (0.98) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL143923 | 0.99 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL12737556 | 0.99 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL10261067 | 0.99 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL24900238 | 0.99 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL19465688 | 0.99 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL1560948 | 0.99 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL1688689 | 0.99 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 | |
| Hydrocortisone SCHEMBL6932400 | 0.99 | HIF1A (1.00) | HIF1AHSD17B10SERPINA6CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891132-A2 | STAT3 TRANSCRIPTION FACTOR INHIBITORS AND METHODS OF USING THE SAME | The Regents of the University of Colorado, a body corporate (US) | 2021-10-13 | — | — | EP | claimed |
| WO-2020118265-A2 | STAT3 TRANSCRIPTION FACTOR INHIBITORS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-06-11 | — | — | WO | claimed |
| US-20150093434-A1 | LIPOSOMAL COMPOSITIONS OF GLUCOCORTICOID AND GLUCOCORTICOID DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERSUSALEM (IL) | 2015-04-02 | — | — | US | claimed |
| US-8932627-B2 | Liposomal compositions of glucocorticoid and glucocorticoid derivatives | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2015-01-13 | — | — | US | claimed |
| US-7744920-B2 | Glucocoricoid is an amphipathic weak acid or base such as methylprednisolone sodium hemisuccinate encapsulated in a liposome; treating rheumatoid arthritis or other autoimmune disease, provided they are not neurodegenerative disorders | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2010-06-29 | — | — | US | claimed |
| US-20080058294-A1 | Glucocorticoid encapsulated within liposome; multiple sclerosis, anticancer agents | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2008-03-06 | — | — | US | claimed |
| US-20080003276-A1 | Glucocoricoid is an amphipathic weak acid or base such as methylprednisolone sodium hemisuccinate encapsulated in a liposome; treating rheumatoid arthritis or other autoimmune disease, provided they are not neurodegenerative disorders | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2008-01-03 | — | — | US | claimed |
| EP-1793804-A2 | USE OF LIPOSOMAL GLUCOCORTICOIDS FOR TREATING INFLAMMATORY STATES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-06-13 | — | — | EP | claimed |
| EP-1791525-A1 | LIPOSOMAL COMPOSITIONS OF GLUCOCORTICOID AND GLUCOCORTICOID DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-06-06 | — | — | EP | claimed |
| WO-2006027787-A1 | LIPOSOMAL COMPOSITIONS OF GLUCOCORTICOID AND GLUCOCORTICOID DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-03-16 | — | — | WO | claimed |
| WO-2006027786-A2 | USE OF LIPOSOMAL GLUCOCORTICOIDS FOR TREATING INFLAMMATORY STATES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-03-16 | — | — | WO | claimed |
| US-20240238311-A1 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL | ANTARES PHARMA, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240216277-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | PHARMOSA BIOPHARM INC. (TW) | 2024-07-04 | — | — | US | disclosed |
| WO-2024133513-A1 | COMPOSITION AND PRODUCTS COMPRISING AN ANTIBIOTIC AND A GLUCOCORTICOID FOR TREATING MASTITIS | VIRBAC (FR) | 2024-06-27 | — | — | WO | disclosed |
| US-20240194304-A1 | Prediction Method, Prediction Device, and Prediction Program for New Indication of Desired Known Drug or Equivalent Material Thereof | KARYDO THERAPEUTIX, INC. (JP) | 2024-06-13 | — | — | US | disclosed |
| WO-1992016235-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF A VARIETY OF DISORDERS UTILIZING ETIANATE AND AGONISTS THEREOF | MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK (US) | 1992-10-01 | — | — | WO | disclosed |
| WO-1991005571-A1 | METHOD FOR PRODUCING BONE MARROW GROWTH CELL FACTORS | UNIVERSITY OF ROCHESTER (US) | 1991-05-02 | — | — | WO | disclosed |
| EP-0381490-A2 | Gene therapy using stromal cells | Greenberger, Joel S. (US) | 1990-08-08 | — | — | EP | disclosed |
| EP-0069147-A1 | LOW MOLECULAR WEIGHT COMPLEX OF POLYRIBOINOSINIC-POLYRIBOCYTIDYLIC ACID AND METHOD OF INDUCING INTERFERON | LERNER, A. Martin (US) | 1983-01-12 | — | — | EP | disclosed |
| WO-1982002338-A1 | LOW MOLECULAR WEIGHT COMPLEX OF POLYRIBOINOSINIC-POLYRIBOCYTIDYLIC ACID AND METHOD OF INDUCING INTERFERON | LERNER MARTIN A | 1982-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238311-A1 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL | G6PC1, MC2R, SLC5A1 | NR3C1 12/4885HIF1A 3279/4885HSD17B10 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.